Moderna says RSV vaccine is 84% effective at preventing disease in older adults

Moderna says RSV vaccine is 84% effective at preventing disease in older adults


A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022.

Johanna Geron | Reuters

Moderna on Tuesday said its vaccine targeting respiratory syncytial virus is effective at preventing disease in older adults.

The vaccine was 83.7% effective at preventing lower respiratory tract disease, defined as two or more symptoms, in people ages 60 and older, according to the Boston biotech company. It was 82.4% effective at preventing lower respiratory tract disease with three or more symptoms.

No safety concerns have been identified during the clinical trial of the vaccine, according to Moderna. The safety and efficacy data from the trial will be published in a peer-reviewed journal, according to the company. The clinical trial has enrolled about 37,000 people across 22 countries.

Moderna said it plans to file an application for approval by the Food and Drug Administration in the first half of this year. There currently is no FDA-approved vaccine for RSV.

Moderna’s stock rose nearly 7% in extended trading.

RSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the Centers for Disease Control and Prevention.

The U.S. suffered an unusually severe RSV season last fall among children and older adults as the public largely stopped practicing public health measures implemented in response to the Covid-19 pandemic, such as masking and social distancing.

Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s successful Covid shots. The Covid vaccine turned Moderna into a global name and delivered windfall profits, but it remains the company’s only commercially available product and demand is fading.

The Boston biotech company faces growing pressure to demonstrate that other products in its pipeline will successfully come to market. Morgan Stanley estimates the market for an adult RSV vaccine is $7 billion to $10 billion.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Health

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients […]

Read More
Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula
Health

Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula

Laura Modi, co-founder and CEO of infant formula startup Bobbie, is on a mission to transform an industry that she says has been stagnant for decades, and shift the culture around how parents feed their babies. Modi, a former Airbnb executive, came up with the idea for Bobbie after the birth of her first child. […]

Read More
Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Health

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]

Read More